

**The Changing Treatment
Landscape of CDK4/6 Inhibitors:
Moving from late to early stages**

Monday, May 09, 2022
Virtual event (6.00-8.00 pm, CET)

CDK **4/6** Inhibitors

Program

6.00 pm

Welcome

Michael Gnant (President of ABCSG, Medical University Vienna)

CDK 4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer

6.10 pm

OS Data: Significance for Clinical Routine and Therapeutic Decision-Making

Michelino De Laurentiis (National Cancer Institute "Fondazione Pascale" Naples)

6.30 pm

Profiling Intrinsic Subtypes: Classification, Clinical Usage and Future Trends

Marija Balic (Vice President of ABCSG, Medical University Graz)

6.45 pm

Discussion

Michael Gnant (President of ABCSG, Medical University Vienna)
and all speakers

6.55 pm

CDK 4/6 and The Role of Selectivity + Q&A

Matt Niederst (Senior Principal Scientist - Oncology NIBR, Novartis Institutes for BioMedical Research)

CDK 4/6 Inhibitors in the Adjuvant and Neoadjuvant Setting

7.20 pm

Updates on Adjuvant Clinical Trial Outcomes and Prospective Research Directions

Daniel Egle (Board Member of ABCSG, Breast Health Center, Medical University Innsbruck)

7.35 pm

Overcoming CDK 4/6 Inhibitor Resistance: SERDS as Emerging Co-Targeting Therapy Strategy

Christian Singer (Vice President of ABCSG, Breast Health Center, Medical University Vienna)

7.50 pm

Discussion

Michael Gnant (President of ABCSG, Medical University Vienna)
and all speakers



Details and registration via

www.universimed.com/CDK4/6_Inhibitors_2022